



International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW
----------------------	---

DOI	https://doi.org/10.31435/ijitss.3(51).2026.6573
------------	---

RECEIVED	17 July 2026
-----------------	--------------

ACCEPTED	16 September 2026
-----------------	-------------------

PUBLISHED	21 September 2026
------------------	-------------------

LICENSE	
----------------	--



The article is licensed under a **Creative Commons Attribution 4.0 International License**.

© The author(s) 2026.

This article is published as open access under the Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW

Mateusz Gawin (Corresponding Author, Email: mateuszg0905@gmail.com)

Sosnowiecki Szpital Miejski sp. z o. o. w restrukturyzacji, Sosnowiec, Poland

ORCID ID: 0009-0006-7409-9586

Emilia Koziara

Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA im. Sierżanta Grzegorza Załogi w Katowicach, Katowice, Poland

ORCID ID: 0009-0005-4454-6085

Mateusz Gadzina

Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA im. Sierżanta Grzegorza Załogi w Katowicach, Katowice, Poland

ORCID ID: 0009-0001-6153-4896

Julia Gawlak

Szpital Specjalistyczny im. Jędrzeja Śniadeckiego w Nowym Sączu, Nowy Sącz, Poland

ORCID ID: 0009-0002-4586-4200

Maciej Krzesimir Kuświk

University Hospital in Poznań, Poznań, Poland

ORCID ID: 0009-0006-1925-204X

Zofia Tarnawska

Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mielęckiego Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland

ORCID ID: 0009-0004-2265-8089

Karolina Figiel

Szpital Powiatowy w Chrzanowie, Chrzanów, Poland

ORCID ID: 0009-0002-2227-5198

Wojciech Sontag

Zagłębiowskie Centrum Onkologii Szpital Specjalistyczny im. Sz. Starkiewicza, Dąbrowa Górnicza, Poland

ORCID ID: 0009-0004-6749-0224

Mateusz Zawisza

Górnośląskie Centrum Medyczne im. Prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland

ORCID ID: 0009-0003-1981-6640

Aleksandra Golec

Górnośląskie Centrum Medyczne im. Prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland

ORCID ID: 0009-0004-9105-350X

ABSTRACT

Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and a profound economic burden on healthcare systems. This review evaluates the clinical efficacy, safety profile, and neurobiological mechanisms of psilocybin, a serotonergic psychedelic, as a targeted intervention for TRD. Current neurobiological evidence indicates that psilocybin, upon conversion to its active metabolite psilocin, acts primarily as a 5-HT_{2A} receptor agonist. This mechanism promotes rapid structural neuroplasticity and modulates the aberrant functional connectivity characteristic of severe depression. Recent randomized clinical trials demonstrate that psilocybin, when administered in controlled settings with psychological support, produces rapid and clinically significant reductions in depressive symptoms. Comparative data indicate that its therapeutic efficacy is at least comparable to standard first-line treatments, such as SSRIs, while frequently offering a faster onset of action. Regarding safety, psilocybin is generally well-tolerated in clinical environments; adverse events are typically mild to moderate and transient. However, the strict requirement for concurrent psychological support and rigorous psychiatric screening highlights a clinical complexity distinct from traditional pharmacotherapies. Overall, current evidence indicates that psilocybin is a promising intervention for TRD with a manageable safety profile in controlled settings. Nevertheless, large-scale, long-term randomized trials are required to determine the durability of its effects and to establish standardized treatment protocols.

KEYWORDS

Psilocybin, Treatment-Resistant Depression, Psychedelic-Assisted Therapy, Neuroplasticity, Rapid-Acting Antidepressants, Serotonin 5-HT_{2A} Receptor

CITATION

Gawin, M., Koziara, E., Gadzina, M., Gawlak, J., Kuświk, M. K., Tarnawska, Z., Figiel, K., Sontag, W., Zawisza, M., & Golec, A. (2026). Efficacy and safety of psilocybin in treatment-resistant depression: A review. *International Journal of Innovative Technologies in Social Science*, 3(51). [https://doi.org/10.31435/ijitss.3\(51\).2026.6573](https://doi.org/10.31435/ijitss.3(51).2026.6573)

COPYRIGHT

© The author(s) 2026. This article is published as open access under the **Creative Commons Attribution 4.0 International License (CC BY 4.0)**, allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

Introduction

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, affecting millions and creating a substantial global health burden (World Health Organization, 2023). Current clinical guidelines for the management of MDD rely primarily on monoaminergic drugs, most commonly selective serotonin reuptake inhibitors (SSRIs), along with psychotherapy (Gautam et al., 2017). While these standard treatments are accessible and effective for many, a large portion of the patient population does not achieve adequate symptom relief.

The clinical limitations of standard antidepressants were clearly demonstrated in the STAR*D trial. The study showed that with each subsequent medication trial, the probability of achieving remission decreases significantly, while the rate of adverse side effects increases (Rush et al., 2006). When a patient does not respond to at least two different antidepressant treatments of adequate dose and duration, the condition is classified as treatment-resistant depression (TRD) (McIntyre et al., 2023).

TRD presents a major challenge not only in clinical practice but also in public health economics. Patients with TRD require more intensive care, experience higher hospitalization rates, and face greater productivity losses. In the United States alone, the economic burden placed on the healthcare system by TRD is substantially higher than that of non-resistant depression (Sussman et al., 2019). This highlights a clear clinical need for treatments that operate outside the traditional monoaminergic framework.

The difficulty in treating TRD suggests that depression involves more than just a simple deficit in serotonin or dopamine levels. Current evidence points toward impairments in synaptic plasticity and cellular resilience within brain networks regulating mood (Duman et al., 2016). Therefore, there is growing interest in rapid-acting interventions capable of promoting structural neuroplasticity rather than simply blocking neurotransmitter reuptake (Duman et al., 2016).

Psilocybin is a serotonergic compound currently under investigation for its capacity to address these specific neurobiological deficits. Following ingestion, it undergoes dephosphorylation to its active metabolite, psilocin, which acts primarily as an agonist at the serotonin 5-HT_{2A} receptor (Nichols, 2016). Activation of this receptor promotes synaptogenesis and modulates the aberrant functional connectivity observed in patients with severe depression (Vollenweider & Preller, 2020).

Consequently, recent clinical trials have evaluated psilocybin as a targeted pharmacological intervention for TRD. This review examines selected literature concerning the clinical efficacy and safety of psilocybin in treatment-resistant populations, alongside the neurobiological mechanisms underlying its antidepressant effects.

Methodology

This article is structured as a narrative review. The primary objective was to evaluate the clinical efficacy and safety of psilocybin specifically in the context of treatment-resistant depression (TRD). Additionally, the review examines the underlying neurobiological mechanisms that contribute to its therapeutic effects. The review examines data from a selected bibliography of 12 peer-reviewed sources, encompassing randomized controlled trials (RCTs), open-label feasibility studies, clinical practice guidelines, and pharmacological literature published between 2006 and 2023. Data were analyzed concerning definitions of TRD, the receptor-level action of serotonergic compounds, and clinical outcomes comparing psilocybin-assisted therapy to baseline measures, placebos, or standard antidepressant treatments.

Results

Clinical Efficacy of Psilocybin

Initial evidence supporting the use of psilocybin for TRD derived from open-label research. Carhart-Harris et al. (2016) conducted a feasibility study in which patients with TRD received two oral doses of psilocybin (10 mg and 25 mg, administered seven days apart) combined with psychological support. The results indicated that the intervention was feasible in a clinical setting and produced measurable reductions in depressive symptoms. Efficacy assessments demonstrated that these clinical improvements were sustained at the three-month follow-up, providing the methodological rationale for subsequent randomized trials.

Subsequent randomized controlled trials have evaluated psilocybin against both standard pharmacological treatments and varying control doses. In a double-blind phase 2 trial comparing psilocybin to the SSRI escitalopram in patients with depression, Carhart-Harris et al. (2021) found no statistically significant difference between the two interventions regarding the primary endpoint, which was the change from baseline on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16). However, secondary clinical outcomes favored the psilocybin group, suggesting that its efficacy is at least comparable to established first-line SSRI therapy.

Further evidence regarding dose-dependent efficacy specifically within TRD populations was reported by Goodwin et al. (2022). In this trial, patients with a treatment-resistant episode of major depression received a single dose of psilocybin at 25 mg, 10 mg, or 1 mg (acting as a control). The study demonstrated that the 25 mg dose resulted in a significantly greater reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores at three weeks post-administration compared to the 1 mg control dose. Notably, the 10 mg dose failed to produce a statistically significant difference from the control, suggesting that 25 mg may represent the necessary single-dose threshold for clinical efficacy in this population.

Similarly, Raison et al. (2023) evaluated the efficacy of a single 25 mg dose of psilocybin compared with an active control (niacin) in patients diagnosed with MDD. Although this trial evaluated a broader major depression cohort rather than an exclusively treatment-resistant population, it demonstrated a statistically significant reduction in depressive symptom severity that was sustained across the 43-day follow-up period. Moreover, measurable clinical improvements emerged within eight days of administration, supporting the rapid onset and short-term durability of psilocybin in severe depressive episodes.

In all evaluated trials, psilocybin was administered with psychological support. As a result, the reported clinical outcomes reflect this combined treatment. These studies did not test the efficacy of psilocybin as a standalone medication (Carhart-Harris et al., 2016; Goodwin et al., 2022).

Safety and Tolerability

Data from the reviewed trials indicate a consistent safety profile for psilocybin when administered in clinical environments. The most commonly reported adverse events include headache, nausea, transient increases in blood pressure, and acute anxiety during drug onset (Carhart-Harris et al., 2021; Goodwin et al., 2022). These effects appear to be generally mild to moderate and typically resolve within 48 hours without additional medical intervention. Importantly, the cited trials reported no instances of severe physiological toxicity, and psilocybin administration was not associated with symptoms of withdrawal or pharmacological dependence (Goodwin et al., 2022).

However, evidence suggests that this safety profile is highly dependent on strict clinical controls. All cited studies utilized rigorous screening to exclude patients with a history of psychosis, bipolar disorder, or severe personality disorders (Carhart-Harris et al., 2016). In addition, trained staff continuously monitored patients during the sessions to manage potential psychological distress. Due to these protocols, the reported safety findings apply primarily to medically supervised settings and do not support unmonitored use.

Discussion

The reviewed literature indicates that psilocybin may represent a viable pharmacological intervention for patients with treatment-resistant depression. The clinical data demonstrate that psilocybin, when administered alongside structured psychological support, appears to facilitate rapid reductions in depressive symptom severity. These outcomes suggest that engaging the 5-HT_{2A} receptor to stimulate neuroplasticity might effectively address the synaptic deficits that typically remain unresponsive to standard monoaminergic reuptake inhibitors (Duman et al., 2016). Neuroimaging data suggest that this receptor activation acutely alters functional connectivity across cortical networks, potentially disrupting the rigid neural signaling patterns characteristic of TRD (Vollenweider & Preller, 2020). This mechanism contrasts with the delayed adaptive changes required by conventional SSRIs.

Despite these neurobiological and clinical findings, several methodological limitations within the current research require careful consideration. A primary challenge is maintaining rigorous double-blind conditions in psychedelic trials. The profound psychoactive properties of psilocybin frequently unmask the treatment allocation to both participants and investigators. This unblinding may introduce significant expectancy bias. In psychiatric research, where primary endpoints rely on subjective clinical rating scales such as the MADRS or QIDS-SR-16, expectancy effects can artificially inflate the reported efficacy in the active treatment group. Future trial designs may need to incorporate active placebos, such as the niacin control utilized by Raison et al. (2023), to attempt to mitigate this issue.

Furthermore, while the rapid onset of symptom reduction is well documented, the long-term durability of these antidepressant effects remains unestablished. Most of the cited clinical trials feature relatively short primary follow-up windows, typically ranging from three to six weeks. Treatment-resistant depression is clinically characterized by high rates of chronic relapse. It remains unclear whether the neuroplastic changes induced by a single or double administration of psilocybin provide sustained remission, or whether patients would require periodic maintenance dosing. Establishing the long-term durability of these clinical benefits is critical before integrating the compound into standard psychiatric care.

Finally, in all reviewed trials, psilocybin was evaluated strictly in conjunction with psychological intervention rather than as a standalone medication. The drug was administered according to a defined clinical protocol that included preparatory sessions, continuous monitoring during the acute pharmacological effects, and subsequent psychological integration. Isolating the independent pharmacological efficacy of the compound from these psychological components remains challenging. This combined approach presents significant barriers to widespread clinical implementation. The requirement for specialized personnel and extended monitoring hours contrasts with the standard outpatient management of conventional antidepressants. This substantial logistical burden may limit broad patient access and offset some of the potential economic benefits of treating TRD.

Conclusions

Current clinical evidence indicates that psilocybin, when administered within structured therapeutic protocols, appears to represent a rapid-acting and viable pharmacological intervention for treatment-resistant depression. By potentially mediating structural neuroplasticity via 5-HT_{2A} receptor activation, the compound is hypothesized to address underlying neurobiological deficits that typically remain unresponsive to conventional monoaminergic reuptake inhibitors. Although recent trials report rapid initial reductions in depressive symptomatology alongside an acceptable short-term safety profile, the available data are currently insufficient to support the widespread integration of psilocybin into routine psychiatric practice.

The implementation of this intervention in standard clinical practice requires overcoming significant methodological and logistical challenges. Future large-scale randomized controlled trials should incorporate extended longitudinal follow-ups to better evaluate the long-term durability of the antidepressant response. Additionally, further research is needed to determine optimal dosing regimens, assess the potential need for maintenance therapy in patients prone to chronic relapse, and improve trial methodology – such as incorporating active placebos – to better separate the pharmacological efficacy from the psychological components. Another significant limitation to routine clinical use is the requirement for extended patient monitoring. Until these challenges are resolved, psilocybin-assisted therapy remains strictly an experimental intervention.

Funding Statement: The study did not receive any external funding.

Conflict of Interest Statement: The authors reported no potential conflict of interest.

REFERENCES

1. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M. A. P., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. *The Lancet Psychiatry*, 3(7), 619–627. [https://doi.org/10.1016/S2215-0366\(16\)30065-7](https://doi.org/10.1016/S2215-0366(16)30065-7)
2. Carhart-Harris, R. L., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. *The New England Journal of Medicine*, 384(15), 1402–1411. <https://doi.org/10.1056/NEJMoa2032994>
3. Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. *Nature Medicine*, 22(3), 238–249. <https://doi.org/10.1038/nm.4050>
4. Gautam, S., Jain, A., Gautam, M., Vohra, A. K., & Gautam, A. (2017). Clinical practice guidelines for the management of depression. *Indian Journal of Psychiatry*, 59(Suppl 1), S34–S50. <https://doi.org/10.4103/0019-5545.196973>
5. Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Campbell, I. G., Carhart-Harris, R. L., Cattell, J., Daniel, A., DeBattista, C., Erritzoe, D., Feifel, D., Fischer, S., & Malievskaia, E. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. *The New England Journal of Medicine*, 387(18), 1637–1648. <https://doi.org/10.1056/NEJMoa2206443>
6. McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., Ly-Uson, J., Mansur, R. B., McAllister-Williams, R. H., Murrough, J. W., Nemeroff, C. B., Nierenberg, A. A., Rosenblat, J. D., Sanacora, G., Schatzberg, A. F., ... Maj, M. (2023). Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions. *World Psychiatry*, 22(3), 394–412. <https://doi.org/10.1002/wps.21120>
7. Nichols, D. E. (2016). Psychedelics. *Pharmacological Reviews*, 68(2), 264–355. <https://doi.org/10.1124/pr.115.011478>
8. Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K. G., Dunlop, B. W., Brown, R. T., Kakar, R. S., Hassman, M., Trivedi, M. H., Robison, R. A., Gukasyan, N., Nayak, S. M., Hu, X., & Usona Institute Study Group. (2023). Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. *JAMA*, 330(9), 843–853. <https://doi.org/10.1001/jama.2023.14530>

9. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederhe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. *The American Journal of Psychiatry*, 163(11), 1905–1917. <https://doi.org/10.1176/ajp.2006.163.11.1905>
10. Sussman, M., O'Sullivan, A. K., Shah, A., Olfson, M., & Menzin, J. (2019). Economic burden of treatment-resistant depression on the U.S. health care system. *Journal of Managed Care & Specialty Pharmacy*, 25(7), 823–835. <https://doi.org/10.18553/jmcp.2019.25.7.823>
11. Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. *Nature Reviews Neuroscience*, 21(11), 611–624. <https://doi.org/10.1038/s41583-020-0367-2>
12. World Health Organization. (2023). *Depressive disorder (depression)*. <https://www.who.int/news-room/fact-sheets/detail/depression>